Podcast Episodes
Back to Search
Analyst Thursdays: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I space
He shares his take on biotech and discusses argenx, Immunovant, AnaptysBio, Apogee, Dianthus, and Viridian.
1 year, 5 months ago
Anglo Nordic Life Science Conference: The CEO of Cure Parkinson's talks about their work, and participating in the International Linked Clinical Trials Initiative
CEO Helen Matthews describes the types of medicines they are supporting for clinical trials (including Ambroxol and GLP-1s), and folding a few progra…
1 year, 5 months ago
Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants
Co-Founder and CEO Thomas Kledal describes the science behind this platform and program. Plus, how having access to donated kidneys is helping the co…
1 year, 5 months ago
On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress
CEO Jason Gardner describes Ampersand's platform that is designed to make medicines act at the site of disease. He also shares updates on partnership…
1 year, 5 months ago
BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degra…
1 year, 5 months ago
Vida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston office
He describes his background in life sciences investing and shares his take on the current state of the sector.
1 year, 5 months ago
After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection
He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision …
1 year, 5 months ago
BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed
He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has plans to use it …
1 year, 5 months ago
Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry
Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how …
1 year, 5 months ago
State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies
Mari Anne Snow describes the advantages she sees nanoparticles having over current modalities like viral vectors, LNPs, and others.
1 year, 5 months ago